To overcome this limitation, we recently tried to develop a novel cancer therapy, gene-interfered ferroptosis therapy (GIFT) [21], by combining cancer cell-specific knockdown of two iron efflux genes, FPN and LCN2 [22–26], with iron oxide nanoparticles (FeNPs) [20]. The gene discussed is SLC40A1; the disease is cancer.